

Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	12 May 2025
TO:	All Oncologists
FROM:	Molecular Pathology, Alberta Precision Laboratories
RE:	Discontinuation of Cell-free DNA Testing for Metastatic Non-small Cell Lung Cancer Patients

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective May 16, 2025 cell-free DNA (cfDNA) testing for patients with non-small cell lung carcinoma will be **NO LONGER** be available at APL.
- This testing was industry sponsored and the program has now closed.
- APL continues to work on the development of an in-house solution and will provide updates as it becomes available. Until such time, no approved alternatives are available for use.

Background

- The Cell-free DNA testing for metastatic non-small cell lung cancer patients' program was industry sponsored and launched in January 2025. The sponsor has informed APL of the closure of their funded program effective May 16, 2025.
- APL is developing an in-house assay to address the testing gap.
- Once the testing criteria are endorsed by the Lab Formulary Committee and approved for clinical testing, APL will resume offering cfDNA testing for non-small cell lung cancer patients.

How this will impact you

- Cell-free DNA assay is <u>NO LONGER</u> available to medical providers as an alternative test for biomarker testing when suitable tumor tissue is not available for stage IIIB or IV non-squamous, non-small cell lung cancer patients.
- All test request received will be cancelled.

Action Required

Discontinue ordering practices for Cell-free DNA testing for metastatic non-small cell lung cancer patients

Effective May 16, 2025

Questions/Concerns

- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology <u>adrian.box@albertaprecisionlabs.ca</u>
- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North cheryl.mather@albertaprecisionlabs.ca

Approved by

- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology Program
- Mark Douesnard, Operations Director, Genetics & Genomics / Molecular Pathology
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), Alberta Precision Laboratories